Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apatinib + fluorouracil + platinum
- Development stage
- Unknown
- Lead developer
- Jiangsu HengRui Medicine Co., Ltd.
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Apatinib is a small molecule tyrosine kinase inhibitor that selectively targets vascular endothelial growth factor receptor-2 (VEGFR-2) to inhibit tumor angiogenesis. In this specific therapeutic regimen, it is combined with fluorouracil (an antimetabolite) and platinum-based chemotherapy (DNA cross-linking agents) to treat recurrent or metastatic esophageal squamous cell carcinoma. This combination therapy is designed to provide synergistic effects by inhibiting tumor blood vessel growth while simultaneously inducing cytotoxic damage to cancer cells. The regimen is currently being evaluated in Phase 2 clinical trials sponsored by The First Affiliated Hospital of Anhui Medical University, with apatinib originally developed by Jiangsu Hengrui Medicine.
- Other names
- Rivoceranib5-fluorouracilcisplatincarboplatin
02
Targets
DNATS (Thymidylate synthase)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on apatinib + fluorouracil + platinum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apatinib + fluorouracil + platinum.